Meta-analysis Outlines Efficacy of Treatments for Relapsed/Refractory Multiple Myeloma

Share this content:
A meta-analysis found that the “best treatment” for prolonging PFS in R/R MM was daratumumab, lenalidomide, and dexamethasone.
A meta-analysis found that the “best treatment” for prolonging PFS in R/R MM was daratumumab, lenalidomide, and dexamethasone.

Since 2000 — after years in which dexamethasone and melphalan was standard treatment — clinicians now have numerous options for patients with relapsed and/or refractory multiple myeloma (R/R MM). These include the immunomodulatory agent, thalidomide, as well as bortezomib, the first proteasome inhibitor introduced in 2004, and 8 other treatments: lenalidomide, pomalidomide, carfilzomib, ixazomib, vorinostat, panobinostat, elotuzumab, and daratumumab.

Yet as the authors of a systematic literature review and network meta-analysis of treatment outcomes noted, “direct comparisons of these novel treatments…are lacking.”1

Chrissy H.Y. van Beurden-Tan, MSc, of the Erasmus Medical Center in Rotterdam, the Netherlands, who was one of the authors of the review, wrote that “bortezomib and lenalidomide were almost simultaneously introduced; both were compared with the former standard treatment, dexamethasone. There is no direct evidence demonstrating whether bortezomib or lenalidomide is superior because no head-to-head comparison has been made. As a consequence, all subsequent treatments were compared with either bortezomib or lenalidomide (with or without dexamethasone). This resulted in a lack of direct comparison among different treatment classes….”

A systematic literature review identified 17 phase 3 randomized controlled trials including 18 treatment options. A network meta-analysis to evaluate the relative efficacy of each treatment found that the “best treatment” for prolonging progression-free survival (PFS) was daratumumab/lenalidomide/dexamethasone, with a hazard ratio (HR) 0.13 vs an HR of 1 for dexamethasone.

Thirteen other combinations had HRs ranging from 0.24 (carfilzomib/lenalidomide/dexamethasone) to 0.76 (thalidomide/dexamethasone). All 3 best treatment options were triple-combination regimens in combination with lenalidomide/dexamethasone, with doublet regimens ranking “at the bottom of the list.”

The authors cautioned that data on adverse-event profiles and quality of life were not assessed, and that overall survival HRs for most of the trials are still immature.

RELATED: Denosumab Delays Skeletal-related Events in Multiple Myeloma

These results apply to “the average patient,” they noted: “selecting the most appropriate treatment option also depends on individual patient characteristics and individual preferences. Our results, however, provide insight into the rank order of the efficacy of treatments and can help doctors to select the most appropriate treatment for each individual patient.”

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters